Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human JAK3 Antikörper:
anti-Mouse (Murine) JAK3 Antikörper:
anti-Rat (Rattus) JAK3 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal JAK3 Primary Antibody für ICC, FACS - ABIN969224
Lai, Jin, Graham, Witthuhn, Ihle, Liu: A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells. in The Journal of biological chemistry 1995
Show all 3 Pubmed References
Human Polyclonal JAK3 Primary Antibody für IF (p), IHC (p) - ABIN681013
Zhang, Liu, Li, Wang, Li, Sun: Jak3 is involved in CCR7-dependent migration and invasion in metastatic squamous cell carcinoma of the head and neck. in Oncology letters 2017
Human Monoclonal JAK3 Primary Antibody für ELISA, FACS - ABIN4327888
Oh, Hwang, Heo: Direct regulation of IL-2 by curcumin. in Biochemical and biophysical research communications 2017
Human Polyclonal JAK3 Primary Antibody für WB - ABIN658182
Yu, Sun, Feng, Tan, Fang, Zhao, Zhao, Pu, Huang, Xiang, Cao, He: MSX3 Switches Microglia Polarization and Protects from Inflammation-Induced Demyelination. in The Journal of neuroscience : the official journal of the Society for Neuroscience 2015
Human Monoclonal JAK3 Primary Antibody für ELISA, FACS - ABIN5581352
Sato, Okano, Tanaka-Kubota, Kimura, Miyamoto, Ono, Yamashita, Mitsuiki, Takagi, Imai, Kajiwara, Ebato, Ogata, Oda, Ohara, Kanegane, Morio: Novel compound heterozygous mutations in a Japanese girl with Janus kinase 3 deficiency. in Pediatrics international : official journal of the Japan Pediatric Society 2016
we report the results of a screening for mutations in SETBP1 (zeige SETBP1 Antikörper) and JAK3 of a cohort of seventy Italian patients with juvenile myelomonocytic leukemia, identifying 11.4% of them harboring secondary mutations in these two genes and discovering two new mutations in the SKI (zeige SKI Antikörper) domain of SETBP1 (zeige SETBP1 Antikörper)
Jak3-mediated phosphorylation of beta-catenin (zeige CTNNB1 Antikörper) suppressed EGF (zeige EGF Antikörper)-mediated epithelial-mesenchymal transition and facilitated epithelial barrier functions by AJ localization of phosphorylated beta-catenin (zeige CTNNB1 Antikörper) through its interactions with alpha-catenin (zeige CTNNA1 Antikörper).
frequency of JAK3 mutations in the JH2 domain was relatively low in extranodal natural killer/T-cell lymphoma, nasal type (NTCL) in contrast to a previous report; study identified novel JAK3H583Y- and JAK3G589D-activating mutations that were oncogenic and sensitive to a JAK3 inhibitor
In natural killer/T-cell lymphoma (NKTL) as a disease model, phosphorylation of EZH2 (zeige EZH2 Antikörper) by JAK3 promotes the dissociation of the PRC2 complex leading to decreased global histone H3 (zeige HIST3H3 Antikörper) lysine 27 methylation levels.
a causal relationship between MLH1 (zeige MLH1 Antikörper)-deficiency and incidence of oncogenic point mutations in tyrosine kinases driving cell transformation and acquired resistance to kinase-targeted cancer therapies, is reported.
JAK3 mediates smooth muscle cell proliferation and survival during injury-induced vascular remodeling.
Data indicate that phosphorylation of Janus kinase 3 (JAK3) and STAT3 (zeige STAT3 Antikörper) transcription factor (STAT3 (zeige STAT3 Antikörper)) was inhibited by latent membrane protein 1 (LMP1 (zeige PDLIM7 Antikörper))-IgG.
analysis of JAK3 kinetic mechanism and inhibition by tofacitinib
patient had a homozygote of the JAK3 mutation, and her parents were heterozygous carriers.
JAK3 up-regulates SGLT1 (zeige SLC5A1 Antikörper) activity by increasing the carrier protein abundance in the cell membrane, an effect enforcing cellular glucose uptake into activated lymphocytes and thus contributing to the immune response.
Small-scale in vivo screening identified several genes, including Cd109 (zeige CD109 Antikörper), that encode novel pro-metastatic factors. We uncovered signaling mediated by Janus kinases (Jaks) and the transcription factor Stat3 (zeige STAT3 Antikörper) as a critical, pharmacologically targetable effector of CD109 (zeige CD109 Antikörper)-driven lung cancer metastasis
JAK1 (zeige JAK1 Antikörper), JAK2 (zeige JAK2 Antikörper), and JAK3 are involved in stimulation of functional activity of mesenchymal progenitor cells by fibroblast growth factor.
JAK mediated signaling is involved in the differentiation and proliferation of mesenchymal progenitor cells.
This study evaluated a chemical genetic toolkit that evaluated a biphasic requirement for JAK3 kinase activity in IL-2 (zeige IL2 Antikörper)-driven T cell proliferation.
Experiments implicate JAK1 (zeige JAK1 Antikörper)/3 signaling in cancer- and myocardial infarction-mediated diaphragm weakness in mice.
Foxp3 (zeige FOXP3 Antikörper) has a rapid turn over in Treg partly controlled at the transcriptional level by the JAK/STAT (zeige STAT1 Antikörper) pathway
JAK3 contributes to the regulation of membrane Kv1.5 (zeige KCNA5 Antikörper) protein abundance and activity, an effect sensitive to ouabain and thus possibly involving Na(+)/K(+) ATPase (zeige ATP1A1 Antikörper) activity.
JAK3 deficiency is followed by down-regulation of cytosolic Ca(2 (zeige CA2 Antikörper)+) release, receptor and store operated Ca(2 (zeige CA2 Antikörper)+) entry and Na(+)/Ca(2 (zeige CA2 Antikörper)+) exchanger activity in dendritic cells.
Data show that IL-4 (zeige IL4 Antikörper) induces upregulation of the junction protein claudin-5 (zeige CLDN5 Antikörper) in endothelial cells (ECs) through activation of Jak/STAT6 (zeige STAT6 Antikörper) and phosphorylation and translocation of FoxO1 (zeige FOXO1 Antikörper) from the nucleus to the cytoplasm.
The protein encoded by this gene is a member of the Janus kinase (JAK) family of tyrosine kinases involved in cytokine receptor-mediated intracellular signal transduction. It is predominantly expressed in immune cells and transduces a signal in response to its activation via tyrosine phosphorylation by interleukin receptors. Mutations in this gene are associated with autosomal SCID (severe combined immunodeficiency disease).
Janus kinase 3 (a protein tyrosine kinase, leukocyte)
, leukocyte Janus kinase
, tyrosine-protein kinase JAK3
, Janus kinase 3 protein-tyrosine kinase
, Janus kinase 3, protein-tyrosine kinase
, Janus tyrosine kinase